HomeAI · summaries
Storia in 5 fonti
Pharmalittle: We're reading about Lilly and Pfizer obesity drug data, Roche and J&J deals, and more
Lilly disclosed new data that provide more details on the safety and tolerability of its next-generation obesity drug retatrutide
Confronto fonti
5 prospettive sulla stessa storiaTimeline cronologica
- ·
statnews.com
Detailed data show Pfizer’s monthly obesity drug continues to show potential
Detailed data from a midstage study offered further evidence that the obesity drug Pfizer acquired from the biotech Metsera could be dosed monthly.
- ·
Lilly shares safety, tolerability data on its next-gen obesity drug
Eli Lilly presented new safety and tolerability data on retatrutide at the annual meeting of the American Diabetes Association on Saturday.
